Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Brief Communication
  • Published:

Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk

Abstract

Using data from a genome-wide association study of 907 individuals with childhood acute lymphoblastic leukemia (cases) and 2,398 controls and with validation in samples totaling 2,386 cases and 2,419 controls, we have shown that common variation at 9p21.3 (rs3731217, intron 1 of CDKN2A) influences acute lymphoblastic leukemia risk (odds ratio = 0.71, P = 3.01 × 10−11), irrespective of cell lineage.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Forest plots of effect size and direction for 9p21.3 (rs3731217) association.
Figure 2: LD structure and association results for the 9p21.3 ALL locus.

Similar content being viewed by others

References

  1. Papaemmanuil, E. et al. Nat. Genet. 41, 1006–1010 (2009).

    Google Scholar 

  2. Treviño, L.R. et al. Nat. Genet. 41, 1001–1005 (2009).

    Google Scholar 

  3. Mullighan, C.G. & Downing, J.R. Leukemia 23, 1209–1218 (2009).

    Google Scholar 

  4. Bateman, C. et al. Blood published online. doi:10.1182/blood-2009-10-25143 (8 January 2010).

  5. Falchi, M. et al. Nat. Genet. 41, 915–919 (2009).

    Google Scholar 

  6. Bishop, D.T. et al. Nat. Genet. 41, 920–925 (2009).

    Google Scholar 

  7. Stacey, S.N. et al. Nat. Genet. 41, 909–914 (2009).

    Google Scholar 

  8. Shete, S. et al. Nat. Genet. 41, 899–904 (2009).

    Google Scholar 

  9. Scott, L.J. et al. Science 316, 1341–1345 (2007).

    Google Scholar 

  10. McPherson, R. et al. Science 316, 1488–1491 (2007).

    Google Scholar 

  11. Sulong, S. et al. Blood 113, 100–107 (2009).

    Google Scholar 

  12. Mirebeau, D. et al. Haematologica 91, 881–885 (2006).

    Google Scholar 

  13. Stranger, B.E. et al. PLoS Genet. 1, e78 (2005).

    Google Scholar 

  14. Kitagawa, Y. et al. J. Biol. Chem. 277, 46289–46297 (2002).

    Google Scholar 

  15. Iacobucci, I. et al. Leukemia 24, 66–73 (2010).

    Google Scholar 

Download references

Acknowledgements

The Kay Kendall Leukemia Fund and Leukemia Research (UK) provided principal funding for the study. Support from Cancer Research UK (C1298/A8362, supported by the Bobby Moore Fund) is also acknowledged. The study made use of genotyping data from the 1958 Birth Cohort which was generated and generously supplied to us by Panagiotis Deloukas of the Wellcome Trust Sanger Institute. For a full list of the investigators who contributed to the generation of the 1958 data, see URL section. We are grateful to S. Richards and J. Burrett (Clinical Trials Service Unit, Oxford) and L. Chilton (Leukaemia Research Cytogenetics Group, Northern Institute of Cancer Research, Newcastle Univ.), J. Simpson (Univ. York), P. Thomson and A. Hussain (Cancer Immunogenetics, School of Cancer Sciences, Univ. Manchester) for assistance with data harmonization. We thank the Leukaemia Research (LR) Childhood Cancer Leukaemia Group (CCLG) Childhood Leukaemia Cell Bank for access to the Medical Research Council ALL trial samples. We are grateful to the UK Cancer Cytogenetics Group (UKCCG) for data collection and provision of samples. P. Thomson (Cancer Immunogenetics, School of Cancer Sciences, University of Manchester) is funded by Children with Leukemia and we acknowledge their support. Genotyping of German cases and controls was partly covered by funding from Tumorzentrum Heidelberg-Mannheim, EU (Food-CT-2005-016320 and Health-F3-2007-2007-200767) and Deutsche Krebshilfe. The Hungarian sample collection was financially supported by grants from the Hungarian Scientific Research Fund (T042500), the Economic Competitiveness Operational Programme, Hungary (GVOP 3.1.1-2004-05-0022/3.0) and NKTH (National Research and Technology) TECH_08-A1/2-2008-0120. M.K. is a scholar of the Fonds de la Recherche en Santé du Québec. D.S. holds the François-Karl Viau Chair in Pediatric Oncogenomics and is also a scholar of the Fonds de la Recherche en Santé du Québec. J.H. is the recipient of a National Sciences and Engineering Research Council Canada Graduate's scholarship. P. Garcia-Miguel and A. Sastre from Hospital Infantil La Paz, Madrid, and J. Luis Vivanco Martínez from Hospital 12 de Octubre, Madrid, were involved in the sample collection of the Spanish samples, and R. Alonso from Centro Nacional de Investigaciones Oncológicas was involved in the genotyping.

We are grateful to all the study subjects and individuals for their participation and, finally, we would also like to thank the clinicians, other hospital staff and study staff who contributed to the blood sample and data collection for this study.

Author information

Authors and Affiliations

Authors

Contributions

R.S.H. and M.G. obtained financial support. R.S.H. designed and provided overall project management. R.S.H. drafted the manuscript with contributions from F.J.H., A.L.S. and M.G.; A.L.S. performed overall project management, development, database development and oversaw laboratory analyses; F.J.H. performed statistical analyses; F.J.H. and A.L.S. performed bioinformatics analyses; J.V. and E.P. performed UK sample preparation and genotyping; E.S. and S.E.K. performed curation and sample preparation of the Medical Research Council ALL 97 trial samples; T.L. and E.R. managed and maintained UKCCS sample data; M.T. performed curation and sample preparation of United Kingdom Childhood Cancer Study samples; J.M.A. and J.A.E.I. performed ascertainment, curation and sample preparation of the Northern Institute for Cancer Research case series. I.P.T. generated and managed UK colorectal cancer control genotypes. A.V.M. and C.J.H. performed UK CDKN2A deletion analysis; N.K., S.O. and H.P.K. carried out German CDKN2A deletion analysis; S.E.D. and Y.M. carried out HapMap and 1000 Genomes imputation; S.R. carried out survival analysis of UK data; M.Z. carried out survival analysis of German data; K.H. oversaw analysis of the German cohort; R.B.P., A.G. and R.K. conducted genotyping of German samples; R. Koehler, M. Stanulla, M. Schrappe and C.R.B. provided German DNA for analysis; D.J.E. and C.S. coordinated the data and sample collection of the Hungarian ALL cohort; A.F.S. genotyped the Hungarian samples; M.K., D.S. and J.H. performed curation and preparation of Canadian samples; A.G.N. was responsible for curation, management and genotyping of Spanish samples. All authors contributed to the final paper.

Corresponding author

Correspondence to Richard S Houlston.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Supplementary information

Supplementary Text and Figures

Supplementary Methods, Supplementary Tables 1–6 and Supplementary Figures 1–3. (PDF 1656 kb)

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sherborne, A., Hosking, F., Prasad, R. et al. Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet 42, 492–494 (2010). https://doi.org/10.1038/ng.585

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ng.585

This article is cited by

Search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer